Open AccessDouble-blind, randomized, controlled clinical trial of norfloxacin for cholera
Author(s) -
Bhattacharya Sk,
Bhattacharya Mk,
P Dutta,
Deblina Dutta,
S. P. De,
S. N. Sikdar,
Anirban Maitra,
Archana Dutta,
Sangita Pal
Publication year - 1990
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.34.5.939
Subject(s) - norfloxacin , placebo , diarrhea , cholera , medicine , vibrio cholerae , double blind , randomized controlled trial , trimethoprim , sulfamethoxazole , antibiotics , gastroenterology , microbiology and biotechnology , virology , biology , ciprofloxacin , genetics , alternative medicine , pathology , bacteria
In a double-blind, randomized clinical trial with 78 adults with acute watery diarrhea and severe dehydration, 37 subjects were positive for Vibrio cholerae. In conjunction with rehydration therapy, 13 patients received norfloxacin, 12 received trimethoprim-sulfamethoxazole (TMP-SMX), and 12 received a placebo. Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion. TMP-SMX was no better than the placebo.